The DAC modification gives this peptide an extended half-life, helping researchers study sustained GH-releasing activity over longer time frames
All of them together, with BPC-157 in the mix, is a different conversation entirely
www.fda.gov/Drugs/DrugSafety/ucm486096.htm
If I have a patient who wants to have a bottle of wine, and eat a huge steak dinner and have 2,000 calories at 10 oclock at night, and [they] think the medication is going to make them feel well and still lose weight, and not change those sorts of dietary habits, theyre not a good candidate. Side effects, in Mounjaros case, can include nausea, vomiting, stomach pain, diarrhea, and a host of similar symptoms
Evidence-Based Management of MASLD and MASH in Patients with Obesity Date: Friday, April 25, 2025 Time: 1:50 PM 2:35 PM East Coast USA Time Location: Potomac AB Description: Up to 90% of individuals with obesity are affected by Metabolic Associated Steatotic Liver Disease (MASLD), and a significant number are at risk of progressing to Metabolic Associated Steatohepatitis (MASH) and liver fibrosis